AVITA Medical CFO buys 1,800 shares in open market

AVITA Medical, Inc. CFO David D. O'Toole increased his stake by buying 1,800 shares of common stock in an open-market purchase at $4.78 per share.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AVITA Medical, Inc. CFO David D. O'Toole increased his stake by buying 1,800 shares of common stock in an open-market purchase at $4.78 per share. After this transaction, he directly owns 141,927 shares, which the disclosure notes include unvested restricted stock units (RSUs).

Insider Trade Summary

Net Buyer: 1,800 shares

Net Buy 1 txn

Insider O'Toole David D

Role CFO

Bought 1,800 shs ($9K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,800	$4.78	$9K

Holdings After Transaction: Common Stock — 141,927 shares (Direct)

Footnotes (1)

F1. Includes unvested RSUs

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AVITA Medical (RCEL) CFO David O'Toole report on this Form 4?

AVITA Medical CFO David D. O'Toole reported an open-market purchase of 1,800 shares of common stock. He bought the shares at $4.78 each, and following this transaction he directly holds 141,927 shares, which the filing indicates include unvested restricted stock units.

How many AVITA Medical shares did the CFO buy and at what price?

The CFO bought 1,800 shares of AVITA Medical common stock at a price of $4.78 per share. This open-market transaction increased his total direct holdings, including unvested restricted stock units, to 141,927 shares after the purchase was completed.

What are David O'Toole's AVITA Medical holdings after this insider purchase?

After the reported purchase, David D. O'Toole directly owns 141,927 AVITA Medical shares. The filing states that this figure includes unvested restricted stock units, showing his combined direct equity position following the 1,800-share open-market acquisition at $4.78 per share.

What type of insider transaction did AVITA Medical's CFO execute?

The transaction was an open-market purchase of common stock by AVITA Medical's CFO. Classified as a "P" code transaction, it represents a direct buy of 1,800 shares at $4.78 per share, rather than an option exercise, tax withholding, or gift-related movement.

Does the Form 4 indicate any derivative positions for AVITA Medical's CFO?

The Form 4 summary shows no derivative transactions or remaining derivative positions for the CFO in this filing. It only reports a single non-derivative open-market purchase of 1,800 common shares, with post-transaction direct holdings of 141,927 shares including unvested restricted stock units.

What does an open-market purchase by AVITA Medical's CFO generally imply?

An open-market purchase typically means the executive chose to buy shares at current market prices. In this case, the CFO added 1,800 shares at $4.78 each, increasing direct holdings to 141,927 shares, which may signal personal confidence but does not guarantee future stock performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/11/2026 - 04:30 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Toole David D

(Last)

(First)

(Middle)

28159 AVENUE STANFORD

SUITE 220 - AVITA MEDICAL

(Street)

VALENCIA

91355

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/11/2026		P		1,800	A	$4.78	141,927⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Includes unvested RSUs

	/s/ David O'Toole	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR